Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB)
will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day
1, and will be followed until Study Day 57. Aurexis is a humanized monoclonal antibody that
is designed to combat Staphylococcus aureus.
The purpose of...Read More
this study is to assess the safety and pharmacokinetics of standard antibiotic
therapy, plus Aurexis or Placebo for treatment of (SAB). Additionally, certain tests and
measurements will be conducted to preliminarily determine if Aurexis demonstrates any benefit
to these patients.Read Less